CR
CRTHF.US CARsgen Therapeutics Holdings Limited
- Market cap
- USD 809M
- P/E
- -
- P/B
- 4.66x
- ROE
- -12.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Oct 2025.
Is CRTHF.US undervalued?
Graham numberThe Graham number of CARsgen Therapeutics Holdings Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CARsgen Therapeutics Holdings Limited fundamental analysis
No fundamental analysis for CARsgen Therapeutics Holdings Limited yet.
CARsgen Therapeutics Holdings Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma. It is also developing autologous CAR-T product candidates, including CT041, which targets Claudin…
Full company profileCARsgen Therapeutics Holdings Limited financial statements
CARsgen Therapeutics Holdings Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 805M | 997M | 1.04B | 1.14B | 0.00 | 25.8M | 0.00 | 0.00 | 39.4M | 126M |
| Gross Profit | 221M | 266M | 275M | 255M | 0.00 | 25.8M | 0.00 | 0.00 | 14.7M | 79.9M |
| Operating Income | 162M | 203M | 211M | 189M | -349M | -587M | -802M | -785M | -574M | -228M |
| EBITDA | - | - | - | - | - | - | -794M | -655M | -713M | -66.5M |
| Net Income | 124M | 157M | 169M | 143M | -1.06B | -4.74B | -892M | -748M | -798M | -97.9M |
| EPS | - | - | - | - | -1.88 | -8.36 | -1.61 | -1.34 | -1.45 | -0.18 |
| Balance Sheet | ||||||||||
| Total Assets | 1.25B | 1.41B | 1.48B | 1.58B | 1.25B | 3.51B | 2.76B | 2.26B | 1.67B | 1.29B |
| Total Liabilities | 622M | 694M | 660M | 699M | 2.93B | 509M | 290M | 456M | 616M | 513M |
| Shareholders' Equity | 631M | 719M | 818M | 879M | -1.68B | 3.00B | 2.47B | 1.80B | 1.06B | 783M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 1.04B | 691M | 2.27B | 1.85B | 1.48B | 1.11B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 23.5M | 154M | 23.3M | 62.3M | -295M | -512M | -643M | -455M | -410M | -237M |
| Capital Expenditure | 1.60M | 1.80M | 2.50M | 2.50M | 18.7M | 178M | 139M | 9.55M | 19.6M | 6.13M |
| Free Cash Flow | - | - | - | - | -314M | -691M | -782M | -464M | -429M | -243M |
| Ratios | ||||||||||
| ROE | 19.7% | 21.8% | 20.6% | 16.3% | - | -158.3% | -36.1% | -41.5% | -75.5% | -12.5% |
| ROA | 9.9% | 11.1% | 11.4% | 9.1% | -84.9% | -135.3% | -32.3% | -33.1% | -47.7% | -7.6% |
| Net Profit Margin | 15.4% | 15.7% | 16.2% | 12.6% | - | -18,380.0% | - | - | -2,024.4% | -77.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CARsgen Therapeutics Holdings Limited dividends
CARsgen Therapeutics Holdings Limited has not paid dividends in the last 10 fiscal years.
Who owns CARsgen Therapeutics Holdings Limited
- Insiders 36.68%
- Institutions 11.09%
- Public & others 52.23%
- Shares outstanding 570M
- Free float 354M
CARsgen Therapeutics Holdings Limited company profile
- Company name
- CARsgen Therapeutics Holdings Limited
- Ticker
- CRTHF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 424
- Fiscal year end
- October
- Address
- Building 2, Shanghai, China
- Phone
- 86 21 6450 1828
- Website
- carsgen.com
About CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The company's products include Zevor-cel (CT053) for the treatment of relapsed/refractory multiple myeloma. It is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in phase I clinical trial for gastric or pancreatic cancer; CT011, which is in phase I clinical trial to treat hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial for the treatment of relapsed/refractory multiple myeloma, relapsed/refractory primary plasma cell leukemia, relapsed/refractory plasma cell leukemia, and newly diagnosed multiple myeloma. In addition, it is developing CT0590 and CT0596, which target B-cell maturation antigen and are in phase I clinical trial for the treatment of R/R MM, PCL; KJ-C2219, which is in phase I for the treatment of B-cell malignancies, systemic lupus erythematosus, and systemic sclerosis; and KJ-C2320 for acute myeloid leukemia (AML) that is in phase I. Further, the company develops KJ-C2526, which is in the pre-clinical stage to treat AML, other malignancies, and senescence; KJ-C2527, which is in the pre-clinical stage to treat gastric cancer; CT1390B, which is in the pre-clinical stage to treat AML; and KJ-C2529, which is in the pre-clinical stage to treat B-cell malignancies. Additionally, it engages in drug research and development, manufacture and import and export handling business. The company was founded in 2014 and is headquartered in Shanghai, China.
CARsgen Therapeutics Holdings Limited management
5- Dr. Zonghai Li M.D., Ph.D.Co-Founder, CEO, Chief Scientific Officer & Chairman of the Board · born 1975
- Dr. Huamao Wang Ph.D.Co-Founder, COO & Executive Director · born 1978
- Dr. Hua JiangExecutive Director · born 1979
- Mr. Haiou ChenExecutive Vice President
- Mr. Wing Yat LuiCompany Secretary · born 1989